3PC-039 Centralised non-hazardous intravenous compounding: improvement of clinical practice

BACKGROUND: In April 2016 the Central IntraVenous Additive Service (CIVAS) began to compound non-toxic injectable therapies with a robotic system.(1) The production started with antiemetic therapies, followed by antibiotic therapies ready to infuse, as cefazoline 1 g in syringes and piperacillin-taz...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Hosp Pharm
Päätekijät: Celestino, S, Leoni, S, Guglielmi, S, Moriconi, L, Marinozzi, A, Polidori, C, Paolucci, D, Bufarini, C
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Group 2018
Aiheet:
Section 3: Production and compounding
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535527/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.91
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia